A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

The purpose of this study is to determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies.

To Learn More Contact
Reference Study ID Number: CA41705 www.roche.com/about_roche/roche_worldwide.htm
888-662-6728 (U.S. and Canada)
global.rochegenentechtrials@roche.com
ClinicalTrials.gov identifier: NCT04221477

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up